195 related articles for article (PubMed ID: 33073291)
1. Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients.
Yoshikawa S; Yoshio S; Yoshida Y; Tsutsui Y; Kawai H; Yamazoe T; Mori T; Osawa Y; Sugiyama M; Iwamoto M; Watashi K; Kawaguchi T; Akita T; Tanaka J; Kikuchi Y; Mizokami M; Oka S; Kanto T; Gatanaga H
J Infect Dis; 2021 Jun; 223(12):2080-2089. PubMed ID: 33073291
[TBL] [Abstract][Full Text] [Related]
2. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
[TBL] [Abstract][Full Text] [Related]
3. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J
J Acquir Immune Defic Syndr; 2020 Aug; 84(5):527-533. PubMed ID: 32692112
[TBL] [Abstract][Full Text] [Related]
4. [A case of hepatitis B virus/human immunodeficiency virus coinfection in a patient who achived hepatitis B surface antigen seroclearance after interferon therapy followed by antiretroviral therapy without developing immune reconstitution inflammatory syndrome].
Mitsumoto F; Murata M; Ikezaki H; Ogawa E; Taniai H; Toyoda K; Otaguro S; Kainuma M; Okada K; Furusyo N; Hayashi J
Kansenshogaku Zasshi; 2012 Nov; 86(6):763-7. PubMed ID: 23367852
[TBL] [Abstract][Full Text] [Related]
5. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
[TBL] [Abstract][Full Text] [Related]
7. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.
Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French M; Ruxrungtham K; Lewin SR
J Infect Dis; 2009 Apr; 199(7):974-81. PubMed ID: 19231993
[TBL] [Abstract][Full Text] [Related]
8. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.
Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C;
Clin Infect Dis; 2018 Jan; 66(1):112-120. PubMed ID: 29020361
[TBL] [Abstract][Full Text] [Related]
9. Acute Immune Reconstitution Inflammatory Syndrome-HBV Flare in an HIV/HBV Coinfected Patient After Antiretroviral Therapy Initiation: Case Report and Literature Review.
Arshad I; Gandhi M; Gossai M; Feinstein A
Am J Case Rep; 2023 Apr; 24():e939210. PubMed ID: 37061778
[TBL] [Abstract][Full Text] [Related]
10. Cytokines and Chemokines Involved in Hepatitis B Surface Antigen Loss in Human Immunodeficiency Virus/Hepatitis B Virus Coinfected Patients.
Urata N; Watanabe T; Hirashima N; Yokomaku Y; Imamura J; Iwatani Y; Shimada M; Tanaka Y
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670625
[TBL] [Abstract][Full Text] [Related]
11. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
12. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
Dezanet LNC; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
J Antimicrob Chemother; 2021 Oct; 76(11):3009-3019. PubMed ID: 34458919
[TBL] [Abstract][Full Text] [Related]
13. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
[TBL] [Abstract][Full Text] [Related]
14. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
[TBL] [Abstract][Full Text] [Related]
15. CD4
Li X; Xu L; Lu L; Liu X; Yang Y; Wu Y; Han Y; Li X; Li Y; Song X; Cao W; Li T
Front Cell Infect Microbiol; 2023; 13():1178788. PubMed ID: 37207191
[TBL] [Abstract][Full Text] [Related]
16. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features.
Morsica G; Ancarani F; Bagaglio S; Maracci M; Cicconi P; Cozzi Lepri A; Antonucci G; Bruno R; Santantonio T; Tacconi L; Baldelli F; Piscopo R; Santoro D; Lazzarin A; D'Arminio Monforte A;
Infection; 2009 Oct; 37(5):445-9. PubMed ID: 19669092
[TBL] [Abstract][Full Text] [Related]
17. HBV infection in untreated HIV-infected adults in Maputo, Mozambique.
Chambal LM; Gudo ES; Carimo A; Corte Real R; Mabunda N; Maueia C; Vubil A; Zicai AF; Bhatt N; Antunes F
PLoS One; 2017; 12(7):e0181836. PubMed ID: 28759595
[TBL] [Abstract][Full Text] [Related]
18. HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy.
Malagnino V; Cerva C; Maffongelli G; Teti E; Foroghi Biland L; Cesta N; De Masi M; Stingone C; Armenia D; Svicher V; Salpini R; Andreoni M; Sarmati L
Sci Rep; 2019 Aug; 9(1):11942. PubMed ID: 31420570
[TBL] [Abstract][Full Text] [Related]
19. HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Belyhun Y; Maier M; Liebert UG
Antivir Ther; 2017; 22(2):97-111. PubMed ID: 27354181
[TBL] [Abstract][Full Text] [Related]
20. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
Maylin S; Boyd A; Delaugerre C; Zoulim F; Lavocat F; Simon F; Girard PM; Lacombe K
Clin Vaccine Immunol; 2012 Feb; 19(2):242-8. PubMed ID: 22190396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
